Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01636258
Other study ID # 12-340
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2012
Est. completion date December 2012

Study information

Verified date May 2022
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To examine whether a lifestyle program results in weight loss and thereby delays or prevents progression of pre-diabetes to diabetes, we propose a pilot randomized controlled trial of 6 weeks duration with 30 participants held at Stephanie Tubbs Jones Health Center. Participants are randomized to receive all of the following: nutrition education, exercise instruction, stress management instruction, and culinary education or follow usual care. Outcomes include: blood sugars and cholesterol, weight, waist circumference, blood pressure, diet, physical activity, perceived stress, and class attendance. Analysis is by Intention to treat analysis of variance. Results will be used to help design larger randomized trial in the future.


Description:

Control group: These participants will continue to receive their usual care from their primary medical care team. Intervention group: The participants will receive nutrition education, exercise instruction, stress management instruction,and culinary education


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date December 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Study participants must: 1. Be capable of giving informed consent 2. Understand and voluntarily sign the informed consent form. 3. Be females at least 18 years of age and identify themselves as African-American 4. Have prediabetes as defined by the American Diabetes Association: history of glycated hemoglobin (HgbA1c) 5.7-6.4 % or fasting blood glucose 100-125 mg/dL (5.6-6.9 mmol/L) (fasting defined as no caloric intake for at least 8 hours), or a 2-hour plasma glucose 140-199 mg/dL (7.8-11.0 mmol/L) during an oral glucose tolerance test (as described by the World Health Organization using a glucose load of 75 g anhydrous glucose dissolved in water) 5. Have a body mass index (BMI, defined as weight in kilograms divided by height in meters squared) greater than or equal to 25 Exclusion Criteria: 1. Current or previous diagnosis of diabetes or a history of HgbA1c = 6.5% or fasting blood glucose = 126 mg/dL (7.0 mmol/L) (fasting defined as no caloric intake for at least 8 hours), or a 2-hour plasma glucose = 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test or a history of classic symptoms of hyperglycemia or hyperglycemic crisis and a random plasma glucose = 200 mg/dL (11.1 mmol/L). 2. Normal glycemia or a currently with a HgbA1c < 5.7% or fasting blood glucose < 100 mg/dL (7.0 mmol/L) (fasting defined as no caloric intake for at least 8 hours), or a 2-hour plasma glucose < 140 mg/dL (11.1 mmol/L) during an oral glucose tolerance test 3. Current or past use of oral hypoglycemic agents (including, but not limited to, metformin, rosiglitazone, pioglitazone, glipizide, and glyburide) or insulin 4. Male gender 5. History of congestive heart failure 6. History of renal failure, dialysis, or creatinine greater than 2 mg/dL 7. History of liver failure or a liver dysfunction with a increase by a factor of 2 above the upper limit of normal in alanine aminotransferase or aspartate aminotransferase 8. History of gastrointestinal disorder that would prevent adherence to the recommended diet (e.g. celiac disease, inflammatory bowel disease, history of bariatric surgery, history of intestinal surgery) 9. Presence of active cancer 10. History of coronary artery disease or cerebrovascular disease 11. History of uncontrolled hypertension 12. Participation in another lifestyle modification trial 13. Pregnancy or lactating or planning to be pregnant 14. Current alcoholism or abuse of recreational drugs 15. Hospitalization for depression in past 12 months 16. Travel plans that do not permit full participation or participant lives too far from Health Center to permit full participation 17. History of bariatric surgery, small bowel resection, or extensive bowel resection 18. Chronic treatment with systemic steroids 19. Current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder 20. Inability to walk two blocks 21. Other medial, psychiatric, or behavioral limitations that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention protocol 22. Amputation of lower limb for nontraumatic causes 23. Self report of HIV-positivity or active tuberculosis 24. Documented history of pulmonary embolus in past six months 25. Chronic obstructive pulmonary disease that would limit ability to follow the study protocol 26. Self-reported chronic hepatitis B or C or cirrhosis; inflammatory bowel disease requiring treatment in past year; Cushing's syndrome; acromegaly (clinical diagnosis or self-report); any major organ transplant 27. Unwilling or uninterested in participating in group lifestyle education sessions 28. Current regular corticosteroid use 29. Active polycystic ovarian syndrome

Study Design


Intervention

Behavioral:
Stress Management
Every other week
Diet
Every other week
Exercise
Every week
Culinary education
Every other week

Locations

Country Name City State
United States Stephanie Tubbs Jones Health Center East Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of "FRESH" Program on Weight Loss Change in weight measured at baseline and followup (at 8-14 weeks). Baseline line and final followup visit (at 8-14 weeks)
Secondary Diet - Daily Calorie Intake Change in daily caloric intake as measured by online 24-hour recall dietary program Baseline and final followup visit (at 8-14 weeks)
Secondary Exercise Change in 7-day average steps/day as measured by pedometer at baseline and followup (at 8-14 weeks). Baseline and final followup visits (at 8-14 weeks)
Secondary Stress Change of Psychosocial Stress (PSS-10) scores (total range 0-40) measured at baseline and followup (at 8-14 weeks). Higher score reflects worse outcome. baseline and followup visit (at 8-14 weeks)
Secondary Sleep Change in self-reported average hours of sleep/night measured at baseline and followup (at 8-14 weeks). baseline and followup visit (at 8-14 weeks)
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Completed NCT02829229 - Community-based Obesity Treatment in African American Women After Childbirth N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4